TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
De novo heart transplant recipients who had received induction therapy with antithomocyte globulin (ATG) were eligible for inclusion.~Recipients of multi-organ transplants or a previous transplant were excluded, as were those with a donor aged \> 70 years, cold ischemia time \>6 hours, patients with severe systemic infection, recipients of ABO incompatible transplants, patients with severe hypercholesterolemia (\>350mg/dL) or hypertriglyceridemia (\>750 mg/dL), patients with past (\<5 years). In order to continue in the study after week 7-11 (period 1), patients had to complete first 7-11 weeks on randomized immunosuppression and none of the following criteria should be present: Ongoing rejection treatment or experience of one grade 3R rejection or two or more grade 2R rejections during first 7-11 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
- Control (Type: EXPERIMENTAL): Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lung Cancer Screening Navigation for Homeless People

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently or formerly homeless~* Have a 30 pack-year smoking history and have smoked within the past 15 years~* Have a Boston Health Care for the Homeless (BHCHP) primary care provider (PCP)~* Proficient in English, assessed with items asking about native language and self-reported comfort communicating in English among non-native speakers~Exclusion Criteria:~* Prior chest computed tomography (CT) imaging in the past 12 months~* Personal history of lung cancer, or current presentation with symptoms concerning for lung cancer (e.g. hemoptysis or unexplained weight loss of \>15 lbs. in the past year)~* PCP is the principal investigator~* Inability to provide informed consent, assessed with knowledge questions about the material presented during the informed consent process that individuals must correctly answer before providing informed consent to participate

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Usual care without patient navigation (Type: NO_INTERVENTION): Participants assigned to this arm will be given basic educational materials on general lung health and referred back to their primary care provider (PCP) for management as per usual practice.
- Usual care with patient navigation (Type: EXPERIMENTAL): Participants assigned to this arm will be informed about lung cancer screening (LCS), provided educational materials on LCS and patient navigation, and offered access to an LCS navigator who will partner with participants and primary care providers (PCPs) to facilitate low-dose computed tomography (LDCT) completion and follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria for participants enrolling with T2DM:~* Type 2 Diabetes treated with a stable dose of metformin at least 500 mg per day for at least 2 months prior to screening visit and use of no other medications for glycemic control.~* HbA1c value between 7.0% and 10.5%, inclusive.~Key Exclusion Criterion for participants enrolling with T2DM:~-Type 1 Diabetes or secondary forms of diabetes.~Key Inclusion Criterion for participants enrolling with obesity:~-Obese (as indicated by screening BMI) non-diabetic adults.~Key Exclusion Criterion for participants enrolling with obesity:~--Type 1 or Type 2 Diabetes or secondary forms of diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Active Obesity (Type: EXPERIMENTAL): Part B
- Placebo Obesity (Type: PLACEBO_COMPARATOR): Part B
- Active T2DM (Type: EXPERIMENTAL): Parts A and C
- Placebo T2DM (Type: PLACEBO_COMPARATOR): Parts A and C

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriate~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2~Exclusion Criteria:~* Concurrent anti-tumor therapy~* Completion of the most recent anti-tumor therapy less than 21 days prior to the initiation of treatment~* Uncontrolled medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vismodegib - Locally Advanced (Type: EXPERIMENTAL): Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
- Vismodegib - Metastatic (Type: EXPERIMENTAL): Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a diagnosis of primary-progressive, secondary-progressive, progressive-relapsing, or relapsing-remitting MS per revised McDonald Committee criteria \[McDonald 2001; Polman 2005\] as defined by Lublin and Reingold \[Lublin and Reingold 1996\] of at least 3 months duration~* Must have an Expanded Disability Status Scale (EDSS) score of 4 to 7, inclusive~* Must have walking impairment, as deemed by the Investigator~Key Exclusion Criteria:~* History of human immunodeficiency virus (HIV)~* Presence of acute or chronic hepatitis. Subjects who have evidence of prior hepatitis infection that has been serologically confirmed as resolved are not excluded from study participation~* Known allergy to fampridine, pyridine-containing substances, or any of the inactive ingredients in the prolonged-release fampridine tablet~* Creatinine clearance (CrCl) of \<80 mL/min~* History of malignant disease~* Presence of pulmonary disease~* A body mass index (BMI) ≥40 (BMI formula: BMI = mass \[kg\]/\[height(m)\]2)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fampridine 10 mg BID (Type: EXPERIMENTAL): Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo 10 mg BID for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Written informed consent prior to participation~* Female and male patients 18 years of age or older with a diagnosis of non-valvular atrial fibrillation.~* At least 6 months of continuous vitamin K antagonist (VKA) treatment for stroke prevention prior to baseline assessment.~* Patients switched to Pradaxa® according to Summary of Product Characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community.~Exclusion criteria:~* Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC)~* Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in non-valvular atrial fibrillation.~* Current participation in any clinical trial of a drug or device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: None): Patients switched from vitamin K antagonist (VKA) to dabigatran

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* infants coming to their own child health center before the age of 13 weeks, and judged to be in good health on the basis of medical history and physical examination~* family living permanently in Tampere, Kangasala or Nokia~* at least one of the parents/guardians is able to communicate fluently in Finnish~* written informed consent obtained from a parent/guardian prior to enrollment in the study~Exclusion Criteria:~* hypersensitivity to any of the components of the vaccines used in the study,~* known or suspected impairment of immunologic function,~* history of invasive pneumococcal disease,~* prior vaccination with any pneumococcal vaccine,~* prior vaccination with hepatitis B vaccine,~* contraindications to routine childhood immunizations~* any medical condition in which, in the opinion of the investigator, the study procedures or vaccinations might cause risk to the health or endanger the well-being of the child

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female at least 9 years of age and older.~* Written and verbal informed consent must be obtained. Participants less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if participant reaches age of consent during the study they should be re-consented at the next study visit).~* Participant must have a score of 3 (moderate) or 4 (severe) on the EGSS assessment at the screening and baseline visit~Key Exclusion Criteria:~* Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.~* Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis.~* Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.~* Participants with a facial beard or mustache that could interfere with the study assessments.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-121 Lotion (Type: EXPERIMENTAL): IDP-121 lotion (tretinoin 0.05 percent \[%\]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
- IDP-121 Vehicle Lotion (Type: PLACEBO_COMPARATOR): IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult subjects aged ≥18 years requiring elective/non-emergent open or laparoscopic general, gynecological, or cardiothoracic surgical procedures.~2. Subject or authorized representative has signed the approved Informed Consent.~3. Subject(s) whose platelet count is ≥100,000 per microliter and International Normalized Ratio (INR) is \<1.5 prior to 24 hours of surgery.~4. Presence of an appropriate TBS identified intra-operatively by the surgeon.~5. Subject(s) undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to TBS identification and treatment.~Exclusion Criteria:~1. Female subjects who are pregnant or nursing.~2. Subject on heparin within 12 hours prior to surgery, or oral Coumadin (warfarin) and/or Factor Xa inhibitors within 3 days prior to surgery.~3. Subject on antiplatelet/P2Y12 inhibitors medication 5 days prior to surgery;~4. Subject is currently participating or plans to participate in any other investigational product or drug trial without prior approval from the Sponsor.~5. Subjects who are known, current alcohol and/or drug abusers.~6. Subjects with any pre-operative findings identified by the surgeon that may preclude conduct of the study procedure.~7. Subjects with any intra-operative findings identified by the surgeon that may preclude the use of study product.~8. Subject with TBS in an actively infected field (Class III Contaminated or Class IV Dirty or Infected; see Appendix 1).~9. TBS is on arteries or veins where application of SURGICEL Powder would present a risk of introducing the study product into an open blood vessel.~10. Major arterial or venous bleeding or major defects in arteries and veins.~11. TBS where silver nitrate or any other escharotic chemicals have been applied.~12. TBS is in, around, or in proximity to foramina in bone, or areas of bony

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SURGICEL Powder (Type: EXPERIMENTAL): SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
- SURGICEL Original (Type: ACTIVE_COMPARATOR): SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- Meet renal function criteria in one of four categories~Exclusion Criteria:~- Unstable or uncontrolled medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Normal renal function): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1
- Group B (End Stage Renal Disease): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1
- Group C (Moderate renal impairment): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1
- Group D (Severe renal impairment): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seasonal Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine in Children in Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months to 10 years~* Agree to seek initial medical care for all medical illness in the study clinic during the study period~* Written informed consent by a parent or legal garden,~* No plan to travel for a long time during the study period.~Exclusion Criteria:~* History of allergy to sulfa drugs or Sulfadoxine-pyrimethamine~* Chronic illness or symptomatic malaria at the time of enrollment

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: NO_INTERVENTION): Control group
- 2 (Type: EXPERIMENTAL): Test group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Male or female patients 40 years of age or older.~* Smoking history of at least 10 pack years.~* Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1\<70% of FVC and on stable respiratory medication.~Exclusion Criteria:~* Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.~* Myocardial infarction in past 6 months.~* Unstable or life threatening arrhythmia in past year.~* Hospitalization for NYHA heart failure class III or IV in past year.~* Active tuberculosis.~* Asthma.~* Pulmonary resection.~* Malignancy treated with radiation or chemotherapy in past 5 years.~* Respiratory infection in 4 weeks prior to screening.~* Known hypersensitivity to anticholinergic drugs or components.~* Known moderate to severe renal impairment.~* Known narrow angle glaucoma.~* Significant symptomatic BPH or bladder neck obstruction.~* Need for oxygen therapy \>12 hr/day.~* Use of oral corticosteroids at unstable doses or \>10 mg/day.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males in good general health and at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia.~Exclusion Criteria:~* Medical conditions that would confound the efficacy evaluation.~* Medical conditions in which it would be unsafe to use an alpha-blocker.~* The use of concomitant drugs that would confound the efficacy evaluation.~* The use of concomitant drugs that would be unsafe with this alpha-blocker.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silodosin (Type: EXPERIMENTAL): Silodosin 8 mg once daily with food
- placebo (Type: PLACEBO_COMPARATOR): Matching Placebo capsule once daily with food

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete